ArticlePDF Available

Conjugated linoleic acid supplementation, insulin sensitivity, and lipoprotein metabolism in patients with type 2 diabetes mellitus1-3


Abstract and Figures

Some animal studies have suggested that conjugated linoleic acid (CLA) supplementation may have therapeutic potential with respect to insulin sensitivity and lipid metabolism, which are important cardiovascular disease (CVD) risk factors associated with type 2 diabetes mellitus. We investigated the effect of CLA supplementation on markers of glucose and insulin metabolism, lipoprotein metabolism, and inflammatory markers of CVD in subjects with type 2 diabetes. The study was a randomized, double-blind, placebo-controlled trial. Thirty-two subjects with stable, diet-controlled type 2 diabetes received CLA (3.0 g/d; 50:50 blend of cis-9,trans-11 CLA and trans-10,cis-12 CLA) or control for 8 wk. A 3-h 75-g oral-glucose-tolerance test was performed, and fasting plasma lipid concentrations and inflammatory markers were measured before and after the intervention. CLA supplementation significantly increased fasting glucose concentrations (6.3%; P < 0.05) and reduced insulin sensitivity as measured by homeostasis model assessment, oral glucose insulin sensitivity, and the insulin sensitivity index (composite) (P = 0.05). Total HDL-cholesterol concentrations increased by 8% (P < 0.05), which was due to a significant increase in HDL(2)-cholesterol concentrations (P < 0.05). The ratio of LDL to HDL cholesterol was significantly reduced (P < 0.01). CLA supplementation reduced fibrinogen concentrations (P < 0.01) but had no effect on the inflammatory markers of CVD (C-reactive protein and interleukin 6). CLA supplementation had an adverse effect on insulin and glucose metabolism. Whereas CLA had positive effects on HDL metabolism and fibrinogen, a therapeutic nutrient should not be associated with potentially adverse effects on other clinical markers of type 2 diabetes.
Content may be subject to copyright.
Conjugated linoleic acid supplementation, insulin sensitivity, and
lipoprotein metabolism in patients with type 2 diabetes mellitus
Fiona Moloney, Toh-Peng Yeow, Anne Mullen, John J Nolan, and Helen M Roche
Background: Some animal studies have suggested that conjugated
with respect to insulin sensitivity and lipid metabolism, which are
type 2 diabetes mellitus.
Objective: We investigated the effect of CLA supplementation on
and inflammatory markersof CVD in subjects with type 2 diabetes.
Design: The study was a randomized, double-blind, placebo-
controlledtrial. Thirty-two subjects withstable, diet-controlled type
and trans-10,cis-12 CLA) or control for 8 wk. A 3-h 75-g oral-
glucose-tolerance test was performed, and fasting plasma lipid con-
centrations and inflammatory markers were measured before and
after the intervention.
Results: CLA supplementation significantly increased fasting glu-
coseconcentrations(6.3%;P 0.05) andreducedinsulinsensitivity
as measured by homeostasis model assessment, oral glucose insulin
sensitivity, and the insulin sensitivity index (composite) (P ҃ 0.05).
Total HDL-cholesterol concentrations increased by 8% (P 0.05),
which was due to a significant increase in HDL
-cholesterol con-
centrations (P 0.05). The ratio of LDL to HDL cholesterol was
significantly reduced (P 0.01). CLA supplementation reduced
fibrinogen concentrations (P 0.01) but had no effect on the in-
flammatory markers of CVD (C-reactive protein and interleukin 6).
Conclusions: CLA supplementation had an adverse effect on insu-
lin and glucose metabolism. Whereas CLA had positive effects on
HDL metabolism and fibrinogen, a therapeutic nutrient should not
beassociatedwithpotentially adverse effectsonotherclinicalmark-
ers of type 2 diabetes. Am J Clin Nutr 2004;80:887–95.
KEY WORDS Conjugated linoleic acid, diabetes, type 2 dia-
betes mellitus, humans, metabolic syndrome, cardiovascular dis-
ease, glucose, insulin sensitivity, lipoprotein metabolism, inflam-
In parallel with the global epidemic of type 2 diabetes are
significant health and socioeconomic burdens (1). Thus, there is
a need to identify effective dietary strategies to attenuate the
effect of type 2 diabetes, which is a heterogeneous disease char-
acterized by target-tissue insulin resistance that cannot be over-
come by
cell hypersecretion (2). The World Health Organiza-
tion (WHO) defined the clustering of metabolic abnormalities
associated with type 2 diabetes as the metabolic syndrome. Fea-
diabetes mellitus coupled with 2 metabolic derangements, in-
cluding obesity, insulin resistance, hypertension, dyslipidemia
(increasedplasmatriacylglyceroland low HDL-cholesterolcon-
centrations); and microalbuminuria (3). Low-grade inflamma-
tion, also a feature of type 2 diabetes (4), has been implicated in
the development of atherosclerosis (5). Cardiovascular disease
(CVD) is the leading cause of morbidity and mortality among
type 2 diabetes patients, as a result of the presence of several
primary risk factors for CVD in this patient population (6).
Although little can be done to avert a genetic predisposition to
through dietary and lifestyle factors is important. Conjugated
linoleic acid (CLA) has received attention as a potential thera-
peutic nutrient with respect to insulin resistance and hyperlipid-
emia (7), which are key characteristics of type 2 diabetes. The
term CLA refers to the positional and geometric isomers of lino-
leic acid with a conjugated double-bond system (8). Animal
feeding studies showed that CLA reduced body fat, increased
lean body mass (9–11), improved plasma lipid metabolism, and
inhibited the progression and promoted the regression of athero-
sclerosis (12–14). There are relatively few human intervention
studies, and the results of those few are mixed. Most of the
evidence regarding body composition suggests that CLA sup-
LDL cholesterol (16, 17) and conflicting effects regarding HDL
cholesterol (16, 18, 19) have been observed after CLA supple-
mentation in humans. A recent study indicated that trans-
10,cis-12 CLA (t10,c12 CLA) supplementation had negative
effects on insulin resistance and biomarkers of oxidative stress
and inflammation in obese men who had signs of the metabolic
combining cis-9,trans-11 (c9,t11) and t10,c12 CLA improved
plasma triacylglycerol concentrations and VLDL metabolism,
without adverse effects on insulin and glucose metabolism, in
From the Nutrigenomics Research Group, Department of Clinical Med-
icine, Trinity Centre for Health Sciences, Dublin (FM, AM, and HMR), and
the Metabolic Research Unit, St James’s Hospital, Dublin (T-PY and JJN).
Supported by the Wellcome Trust, United Kingdom.
Address reprint requests to HM Roche,Trinity Centre for Health Sci-
ences, St James’s Hospital, James’s Street, Dublin 8, Ireland. E-mail:
Received February 2, 2004.
Accepted for publication April 7, 2004.
887Am J Clin Nutr 2004;80:887–95. Printed in USA. © 2004 American Society for Clinical Nutrition
by guest on June 13, 2013ajcn.nutrition.orgDownloaded from
healthy subjects (17). These conflicting results may reflect dif-
ferences in study duration, cohort composition, study settings,
and, most important, supplement composition. CLA is a very
heterogenous compound, and distinct isomer-specific effects
and t10,c12 CLA, have contrasting metabolic and molecular
effects. Feeding c9,t11 CLA improved lipid and glucose metab-
and dylipidemia in ob/ob mice (7, 22).
The objective of the present study was to determine the effect
of CLA supplementation (providing equal proportions of c9,t11
and t10,c12 CLA) in patients with stable, diet-controlled type 2
diabetes. To date no study hasinvestigated the metabolic effects
ofCLAsupplementationinthesepatients.Several key aspectsof
the metabolic syndrome, including insulin and glucose metabo-
lism, lipoprotein metabolism, and markers of coagulation and
inflammation, were measured to ascertain the effect of CLA in
persons with diet-controlled type 2 diabetes.
This study was approved by the Joint Ethics Committee of St
JamessHospital and theFederated Dublin VoluntaryHospitals,
explained before written informed consent was obtained from
a2030% change in triacylglycerol concentrations, assuming a
type I error of 0.05 and a power of 0.9. Thirty-two subjects with
type 2 diabetes who attended the Diabetic Day Care Centre at St
diet therapy alone completed the trial. All subjects had stable
metabolic control with a glycatedhemoglobin (HbA
) concen
tration of 6.83 0.18 mmol/L and a mean fasting blood glucose
concentration of 7.33 0.24 mmol/L. No subjects were receiv-
ing pharmacologic treatment for glucose control or lipid-
lowering purposes. Hypertension was present in approximately
one-half of the subjects. However, only subjects whose blood
pressurewasunderstablecontrolparticipatedin the study.There
was no difference in the prevelance of hypertension between the
2 groups. In addition, there was no documentation of macrovas-
culardisease in the medical notes of any participant. All subjects
hadstablebodyweight.Allwerefollowing healthy eatingguide-
lines as recommended by the American Diabetes Association
(23). The study subjects did notconsume fatty acid supplements
or other dietary products known to affect metabolic markers of
type 2 diabetes.
Study design
This randomized, double-blinded, placebo-controlled study
was conducted on a free-living, outpatient basis. Subjects re-
ceived 3.0 g CLA/d (six 0.5-g capsules; a 50:50 isomer blend of
c9,t11 and t10,c12 CLA) or placebo (blend of palm oil and soya
bean oil) for 8 wk. The placebo was designed to contain a blend
of fatty acids that was representative of a habitual Western diet
by Loders Crooklann (Wormeveer, Netherlands). Each volun-
wk 4. A capsule count was completed midway and at the end of
the supplementary period. All participants were asked to main-
tain their usual dietary and lifestyle habits. The effect of changes
in diet, weight, and physical activity was explained to the sub-
jects. There was no change in prescribed medication (ie, antihy-
pertensives) throughout the trial.
Dietary assessment
Mean daily dietary intake was assessed by using two 4-d food
records, one completed immediately before the study and the
other completed at the end of the supplementation period (26).
Household measures, standard food portions, and a food atlas
was analyzed for macronutrient composition with the use of
NETWISP software (version 2.0; Tinuviel Software, War-
rington, United Kingdom), which was modified to include the
composition of frequently consumed foods that were not part of
the database. This additional information was obtained from the
nutrient information panel supplied by the manufacturers.
Clinical investigations
Subjects attended the Metabolic Unit, Department of Endo-
crinology, St Jamess Hospital, for blood sampling after a 12-h
overnight fast before and after intervention (weeks 0 and 8).
Subjects abstained from strenuous exercise and alcohol intake
for 24 h before the examination and refrained from smoking on
the morning of the examination. No medications (eg, antihyper-
tensives) were taken before the clinical investigations. On the
morningofeachinvestigation,afastingblood sample wasdrawn
andastandard 3-h,75-g oral-glucose-tolerance test(OGTT) was
performed. The 75 g anhydrous glucose equivalent (Polycal;
Nutricia Clinical, Trowbridge, United Kingdom) was consumed
in 300 mL water within 5 min. Blood samples were collected at
0, 30, 60, 90, 120, and 180 min for the measurement of plasma
glucose and serum insulin and C-peptide concentrations.
Biochemical analysis
Blood for measurement of cholesterol, triacylglycerol, LDL,
interleukin 6 (IL-6), insulin, and C-peptide concentrations was
collected in serum tubes (Becton Dickinson, Oxford, United
Kingdom). Blood for HDL and VLDL analysis was collected in
EDTA-coated evacuated tubes (Becton Dickinson). Samples for
glucose analysis were collected in tubes containing sodium flu-
oride, and blood for fibrinogen, C-reactive protein (CRP), and
Fatty acid composition of the conjugated linoleic acid (CLA) supplement
and the control supplement
Control CLA
% by wt of total fatty acids
Fatty acid composition (%)
16:0 38.52 4.82
18:0 4.70 2.28
18:1 34.84 10.17
18:2nҀ6 17.89 1.73
Saturated fatty acids 44.97 8.16
CLA isomers (%)
Total CLA 0.06 73.83
cis-9, trans-11 CLA 0.06 35.62
trans-10, cis-12 CLA ND 38.21
Supplements were given as free fatty acid. ND, not detectable.
by guest on June 13, 2013ajcn.nutrition.orgDownloaded from
ton Dickinson). Serum samples were allowed to clot for 1 h.
Samples for lipid, glucose, insulin, C-peptide, and IL-6 analyses
were centrifuged immediately at 1400 ҂ g for 10 min at room
temperature. Citrated samples for CRP and fibrinogen measure-
mentswerecollectedandthencentrifugedat2000҂ gfor20min
atroomtemperature.Bloodsamplescollectedfor fatty acidanal-
ysis were centrifuged at 200 ҂ g for 20 min at room temperature
to harvest the platelet pellet and platelet-poor plasma. All of the
samples listed above were frozen immediately and stored at
Ҁ70 °C for subsequent analysis.
Plasma samples were analyzed for triacylglycerol and choles-
terol concentrations with the use of enzymatic colorimetric as-
says supplied by Instrumentation Laboratory (Warrington,
United Kingdom) on an IL Monarch centrifugal analyzer (In-
strumentation Laboratory) as previously described (28). Total
-, and HDL
-cholesterol concentrations were de
termined after precipitation with Immuno Quantolip total HDL
reagent (both: Immuno Ag, Vienna) as previously described
(17). LDL-cholesterol concentrations were measured after pre-
cipitation of LDL by using a Randox precipitation reagent (Ran-
dox, Antrim, United Kingdom) according to the manufacturers
instructions. VLDL was isolated according to published labora-
tory methods (17). VLDL, LDL, and HDL lipid compositions
were determined according to published methods (28). VLDL
apolipoprotein B (apoB) was measured by using a turbidimetric
assay (Instrumentation Laboratory) on the IL Monarch centrif-
ugal analyzer (29).
Plasma glucose concentrations were measured by using enzy-
matic determination based on the glucose oxidase principle
(BioMerieux, Marcy-lEtoile, France). Serum insulin and
C-peptide concentrations were measured by using solid-phase,
two-site fluoroimmunometric assays (AutoDELFIA Insulin kit
and AutoDELFIA C-Peptide kit, respectively; Wallac Oy,
Turku, Finland) on a 1235 AutoDELFIA automatic immunoas-
say system (Wallac Oy). Hb A
was assessed by using a fully
automated HPLC analyzer (Menarini-Arkray HA 8140; Arkray
KDK, Kyoto, Japan).
IL-6 and CRP assays were performed by using human high-
sensitivity immunoassay test kits (Biosource, Camarillo, CA,
and BioCheck Inc, Burlingame, CA, respectively) according to
each manufacturers instructions. Fibrinogen clotting activity
described (30).
For each marker, both preintervention and postintervention
and 3.15%, respectively. The interassay CV for fibrinogen was
3.25%. Insulin, C-peptide, Hb A
, glucose, and microalbumin
concentrations were analyzed in the laboratory of St Jamess
Hospital and were acceptable according to the routine internal
and external standards applied.
Fatty acid compositional analysis
Protocol compliance was verified by conducting a capsule
theuse ofgas liquid chromatography (GLC). Totalplasma lipids
were isolated by using the method of Folch et al (31), as previ-
ously described (17). Methyl esters of total plasma lipid were
prepared by adding 0.5 mL of 0.01 mmol NaOH/L in dry meth-
anol and then adding 0.5 mL boron trifluoride as described
previously (17). Total plasma lipid fatty acid composition was
determined by using Shimadzu GC-14A GLC (Mason Technol-
ogies, Dublin) fitted with a Shimadzu C-16A integrator (Mason
Technologies) and a CP Sil 88 fused silica column (50 m ҂
0.22 mm, 0.2
m file thickness; Chrompack Ltd, Middelburg,
Netherlands). Conditions for GLC analysis were as follows: N
was the carrier gas, and the column initial temperature (180 °C)
was increased (at a rate of 5 °C/min) to 195 °C, held for 40 min,
and then increased (by 2 °C/min) to 220 °C and held for 20 min.
Plasma fatty acids were identified according to their retention
times in comparison with a fatty acid methyl ester standard
(Sigma-Aldrich, Dublin) spiked with known concentrations of
transmethylated c9,t11 and t10,c12 CLA isomers (Cayman
Chemical, Ann Arbor, MI). Plasma fatty acid composition was
calculated as a percentage of total fatty acids.
Anthropometric measurements
Body weight was measured on an electronic balance (to the
nearest0.1 kg) with subjects wearing light clothing but no shoes.
Height was assessed by using a stadiometer that measured to the
nearest 0.1 cm. Waist girth was measured at the minimum cir-
measured at the maximum width over the greater trochanters.
Waist-to-hip ratio (WHR) was calculated from these measure-
ments (32). Bioelectric impedance analysis was measured in
subjects in the erect position by using a body fat analyzer (TBF-
300; Tanita Corporation, Arlington Heights, IL). Percentage
body fat was calculated by using the manufacturers pro-
grammed equations.
Data preparation and statistical analysis
All statistical analysis was conducted by using DATA DESK
are presented as mean ( SEM). When necessary, values were
transformed to give a normal Gaussian distribution. The post-
prandial data were expressed in summary formie, area under
the postprandial curve (AUC), incremental area under the post-
prandial curve (IAUC), maximum postprandial concentration
), and time to maximal postprandial concentration (T
These data were used to investigate postprandial variations be-
tween the supplement groups. AUC was calculated by using the
trapezium rule (33), and IAUC was calculated as the total incre-
mental AUC according to Le Floch (34). Homeostasis model
assessment (HOMA) was calculated as fasting glucose (mg/dL)
multiplied by fasting insulin (
U/mL) divided by 22.5 (35). Quan-
titative insulinsensitivity check index (QUICKI) was calculated as
)ѿ log(G
)], where I ҃ insulin and G ҃ glucose (36).The
by Matsuda et al (37). Oral glucose insulin sensitivity (OGIS) was
calculated by using the published formula (38).
line value of the outcome variable, was used to identify signifi-
cant changes in biochemical values after the supplementation
concentrations because baseline values differed between the
groups. Three-way analysis of variance (ANOVA) with subject,
treatment, and intervention as independent variables and a
by guest on June 13, 2013ajcn.nutrition.orgDownloaded from
treatment-by-intervention interaction was used to identify sig-
nificant changes in plasma fatty acid composition. Repeated-
measures ANOVA with a treatment-by-time interaction was
used to investigate significant differences in postprandial re-
sponses between the study groups. Post hoc statistical analysis
was conducted by using Scheffes test. A P value 0.05 was
considered significant.
Subject characteristics and intervention details
Baseline characteristics of the 2 study groups are summarized
in Table 2. The mean age, weight, body mass index (BMI; in
),waist circumference, hip circumference, WHR, percent
age body fat, and duration of diabetes did not differ significantly
between groups. The anthropometric measurements did not
change after either the CLA or control supplements (data not
shown). Study compliance was assessed by a pill count, total
plasma fatty acid composition, and dietary assessment. The sub-
jects consumed 96.16% of the prescribed supplements. Compli-
ance did not differ significantly between the study groups:
CLA groups, respectively. The fatty acid compositions of total
plasma lipids are shown in Table 3. The c9,t11 CLA concentra-
tions increased by 89% after CLA supplementation (P 0.001).
The t10,c12 CLA isomer was undetectable in most samples and
was not affected by CLA supplementation. Linoleic acid (18:
2nҀ6) concentrations increased significantly in the CLA group
(P 0.01). Dietary analysis, based on two 4-d food records, one
completed before and the other completed after the intervention,
showed that mean daily energy, macronutrient, dietary fiber,
cholesterol, alcohol intake, and percentage contributions to total
or food energy did not differ significantly after CLA or placebo
supplementation (data not shown). In addition, mean daily nu-
trient intakes did not differ significantly between groups before
or after intervention (data not shown).
Insulin and glucose metabolism
The effect of CLA supplementation on a range of measures of
insulin sensitivity and glycemic control is shown in Table 4.
CLAsupplementation(P 0.05). HOMAwasalsosignificantly
higherafter CLAsupplementation thanafter controlsupplemen-
tation (P ҃ 0.05). Both OGIS and the ISI (composite) were
significantlylowerafterCLA supplementation thanaftercontrol
supplementation (P ҃ 0.05 and P 0.05, respectively). The
QUICKI measure of insulin sensitivity and the Hb A
and mi
croalbumin concentrations were not significantly altered by
CLA supplementation. The postprandial glucose, insulin, and
C-peptide concentrations in response to the OGTT are shown in
Figure1. Repeated-measures ANOVA showed that plasma glu-
cose, serum insulin, and C-peptide concentrations increased sig-
nificantly (P 0.001) during the OGTT. Both before and after
Baseline characteristics of the study population by treatment group
Control group
(n ҃ 16)
CLA group
(n ҃ 16)
Age (y) 58.1 2.7 63.8 2.2
Weight (kg) 88.2 3.8 84.37 3.1
BMI (kg/m
30.7 1.2 29.1 1.0
Waist circumference (cm) 101.1 2.6 102.7 2.5
Hip circumference (cm) 110.0 2.8 108.2 1.9
WHR 0.92 0.02 0.95 0.02
Percentage body fat (%) 33.2 2.3 32.9 2.5
Duration of diabetes (mo) 32.9 7.4 34.5 5.74
All values are x SEM. CLA, conjugated linoleic acid; WHR,waist-
to-hipratio. Therewere nosignificantdifferencesinbaselinevaluesbetween
the 2 groups (one-way ANOVA).
Fatty acid composition of total plasma lipids before and after conjugated linoleic acid (CLA) supplementation or placebo for 8 wk
Fatty acid
Control group
(n ҃ 16)
CLA group
(n ҃ 16)
Week 0 Week 8 Week 0 Week 8
% by wt of total fatty acids
16:0 24.80 0.55 25.52 0.58 25.75 0.57 26.3 0.50
16:1 2.16 0.22 1.79 0.13 2.17 0.22 2.24 0.19
18:0 9.96 0.40 10.97 0.55 10.3 0.40 10.78 0.40
18:1 18.58 0.85 17.66 0.80 18.46 0.88 19.66 0.96
18:2nҀ6 20.73 0.72 21.26 0.91 19.21 0.74 21.90 1.18
18:3nҀ6 0.26 0.02 0.23 0.01 0.20 0.02 0.24 0.01
18:3nҀ3 0.49 0.08 0.57 0.1 0.44 0.06 0.32 0.05
CLA 0.28 0.04 0.32 0.05 0.37 0.06 0.7 0.08
20:2 0.27 0.02 0.29 0.02 0.30 0.01 0.29 0.02
20:3nҀ6 2.52 0.15 2.59 0.24 2.31 0.25 2.30 0.14
20:4nҀ6 8.58 0.37 9.06 0.53 9.36 0.56 8.66 0.46
20:5nҀ3 1.30 0.16 1.24 0.24 1.67 0.32 1.18 0.14
22:4nҀ6 0.41 0.03 0.43 0.06 0.70 0.18 0.40 0.03
22:6nҀ3 2.94 0.25 2.47 0.23 3.15 0.29 3.16 0.26
All values are x SEM.
Significantly different from week 0, P 0.01 (three-way ANOVA).
Significant difference between groups after 8 wk of supplementation (treatment ҂ intervention interaction), P 0.001 (three-way ANOVA).
by guest on June 13, 2013ajcn.nutrition.orgDownloaded from
the intervention, postprandial glucose concentrations were sig-
nificantly higher in the CLA group, whereas postprandial
C-peptideconcentrationsweresignificantly higher inthecontrol
group (P 0.01). Fasting glucose concentrations were signifi-
cantly higher after CLA supplementation than after control sup-
plementation (P 0.05). Postprandial glucose concentrations
neither supplement had a significant effect on fasting or post-
response after the OGTT were not significantly altered by CLA
or control supplementation (data not shown).
Lipoprotein metabolism
Fasting serum and lipoprotein lipid concentrations before and
after supplementation are shown in Table 5. There was no sig-
nificant effect of either CLA or control supplementation on total
or LDL-cholesterol concentrations. Total HDL-cholesterol con-
centrations were significantly increased after CLA supplemen-
tation (P 0.05). The 7.9% increase in total HDL-cholesterol
concentration was due to a significant increase in HDL
trations after CLA supplementation (P 0.05). LDL:HDL cho-
lesterol was significantly reduced after CLA supplementation
(P 0.01). Serum and VLDL triacylglycerol and VLDL-
cholesterol concentrations were not significantly altered by ei-
ther supplement. VLDL apoB concentrations were significantly
higherafter CLAsupplementation thanafter controlsupplemen-
tation (P 0.05). Triacylglycerol-poor lipoprotein triacylglyc-
by the CLA or placebo supplements (data not shown).
Markers of inflammation and coagulation
The effect of CLA and control supplementation on inflamma-
tion and coagulation was also determined. Plasma fibrinogen
concentrations were significantly lower after CLA supplemen-
tationthanaftercontrol supplementation (315.11 7.34,317.36
5.56, 310.15 5.84, and 294.30 5.87 mg/dL for control
week 0, control week 8, CLA week 0, and CLA week 8, respec-
tively)significantly more than did control supplementation (P
0.01). Serum IL-6 and plasma CRP concentrations were not
altered by CLA or control supplements (data not shown).
This study determined the effect of CLA supplementation on
several key CVD risk factors in a group of healthy subjects with
well-controlled type 2 diabetes that was treated by diet therapy
alone. In view of the increased risk of CVD associated with
diabetes, it is important to investigate the ability of nutritional
therapies to attenuate the effect of modifiable risk factors asso-
ciated with CVD in this high-risk patient group. Glucose toler-
ance and insulin sensitivity are central to type 2 diabetes, and
therefore an OGTT was performed, and a number of fasting and
postprandial indexes were investigated. CLA supplementation
had a negative effect on fasting glucose concentrations. HOMA
is a common measure of insulin resistance, derived from fasting
insulin and glucose concentrations. In our study, CLA supple-
mentation had an adverse effect on insulin resistance, increasing
HOMA by 19%. Postprandial plasma glucose concentration has
been cited as an independent risk factor for CVD in persons with
type 2 diabetes (39). Hepatic and peripheral insulin sensitivities
differ considerably within subjects, and a combination of fasting
andpostprandialmeasuresprovides a morecomprehensivemea-
sure of insulin sensitivity than does either measure alone (37).
Postprandial glucose and insulin concentrations did not increase
significantly after CLA supplementation, but the ISI (compos-
ite), which was derived from both fasting and postprandial mea-
sures, decreased significantly after CLA supplementation. In
addition, OGIS, which is also based on both fasting and post-
prandial data, was significantly reduced by CLA supplementa-
tion. It has been proposed that OGIS represents a better index of
insulin sensitivity because it has a more physiologic basis than
the empirical formulas have (38). Moreover, OGIS strongly cor-
relates with the hyperinsulinemic-euglycemic glucose clamp
measures of insulin sensitivity in diabetic subjects, whereas
HOMA and ISI (composite) do not (38).
This study investigated the effect of a CLA supplement that
provides equal proportions of the c9,t11 and t10,c12 CLA iso-
mers, the composition of which reflects most commercially
availableCLAsupplements. Itisinteresting thatthis supplement
did not adversely affect insulin and glucose metabolism in
healthy subjects (17). The present study confirms work that
showed that t10,c12 CLA supplementation had a negative effect
on insulin resistance in obese men with signs of the metabolic
Measurements of insulin sensitivity and glycemic control before and after conjugated linoleic acid (CLA) supplementation or placebo for 8 wk
Control group
(n ҃ 16)
CLA group
(n ҃ 16)
Week 0 Week 8 Week 0 Week 8
Fasting glucose (mmol/L) 7.33 0.40 7.09 0.35 7.34 0.27 7.8 0.28
Fasting insulin (pmol/L) 54.94 5.10 50.68 7.60 52.13 7.90 57.87 8.86
HOMA 3.00 0.35 2.59 0.42 2.81 0.42 3.35 0.54
QUICKI 0.33 0.005 0.36 0.025 0.34 0.007 0.33 0.007
ISI (composite) 3.98 0.40 6.26 1.89 4.58 0.64 4.11 0.54
OGIS 353.63 19.0 362.40 16.41 341.08 15.89 329.84 16.38
Hb A
6.73 0.12 6.59 0.18 6.93 0.33 6.63 0.16
Microalbumin 3.22 0.77 3.32 0.72 1.61 0.31 1.49 0.21
All values are x SEM. HOMA, homeostasis model assessment; QUICKI, quantitative insulin sensitivity check index; ISI (composite), insulin
sensitivity index (composite); OGIS, oral glucose insulin sensitivity; Hb A
, hemoglobin A
Significant difference between groups after 8 wk of supplementation (analysis of covariance):
P 0.05,
P ҃ 0.05.
by guest on June 13, 2013ajcn.nutrition.orgDownloaded from
FIGURE1.Mean( SEM) plasmaglucose,serum insulin,and C-peptideconcentrationsin responseto theadministrationof 75g anhydrousglucosebefore
and after conjugated linoleic acid (CLA) supplementation (3 g/d) or placebo for 8 wk in the control group (week 0, ; week 8, ) and the CLA group (week
0, F; week 8, ). By repeated-measures ANOVA, there was a significant time effect for glucose, insulin, and C-peptide (P 0.001) and a treatment-by-time
effect for plasma glucose and serum C-peptide (P 0.01). Fasting plasma glucose concentrations were significantly higher after CLA supplementation, P
0.05 (analysis of covariance).
by guest on June 13, 2013ajcn.nutrition.orgDownloaded from
syndrome (20). The discrepancy between studies reflects the
Our group found that feeding a t10,c12 CLArich diet induced a
profound prodiabetic effect, whereas feeding the c9,t11 CLA
isomerimproved lipid and glucose metabolism in ob/ob mice (7,
22). Other groups have shown that feeding a blend of CLA
isomers induced marked lipodystrophic insulin resistance and
glucose intolerance in the C57BL/6J mouse model of diabetes
(40). In contrast, another group showed that feeding a 50:50
blend of c9,t11 and t10,c12 CLA reduced glucose and insulin
concentrations in male ZDF rats (41, 42). Clearly the effect of
CLA supplementation is isomer-specific and dependent on the
diabetic risk of the experimental model. In the case of subjects
with type 2 diabetes, a CLA blend containing equal quantities of
c9,t11 and t10,c12 CLA does not improve insulin and glucose
CLA supplementation had a positive effect on HDL-
cholesterolconcentrationsinthis study. Ithasbeen reported that,
for each increase of 0.03 mmol/L in HDL-cholesterol concen-
tration, there is a 23% reduction in coronary heart disease
(CHD) risk (43). Thus, the increase in HDL cholesterol after
CLA supplementation could represent a 7.311% reduction in
promote reverse cholesterol transport (RCT; 44). Because RCT
is impaired in persons with type 2 diabetes (45), the potential
ability of CLA to restore RCT would be favorable.CLA supple-
mentation reduced LDL-cholesterol concentrations (8.8%), al-
beit not significantly, but that reduction contributed to a greater
reduction (14.5%) in LDL:HDL cholesterol. The Helsinki Heart
Study showed that LDL:HDL cholesterol was the single best
predictor of cardiac events (46). Therefore, the effect of CLA
supplementation on LDL:HDL cholesterol in type 2 diabetes
may be of clinical benefit.
The lack of effect on CLA on triacylglycerol metabolism con-
trasts with our previous findings (17). It is possible that this
triacylglycerol metabolism, an effect that may be linked to the
adverse effects of CLA on glucose and insulin metabolism.
VLDL apoB concentrations increased after CLA supplementa-
concentrations after CLA supplementation. Increased intrahe-
patic lipid substrate (triacylglycerol and cholesterol) delivery is
a critical factor regulating hepatic VLDL apoB secretion. How-
ever, neither triacylglycerol nor cholesterol concentrations were
significantly altered after CLA supplementation. Increased
VLDL apoB concentrations are associated with insulin resis-
in this study may be related to increased insulin resistance.
Elevated plasma concentrations of fibrinogen, CRP, and IL-6
are associated with increased risk of CHD and the severity of
atherosclerosis (49). Both low-grade inflammation (4) and a
prothrombotic risk profile have been reported in persons with
type 2 diabetes (50). CLA supplementation reduced plasma fi-
brinogen concentrations, which have a key role in coagulation
(51). CRP concentrations showed a nonsignificant reduction
CLA supplementation had no effect on markers of blood coag-
ulation and platelet function in a small group of healthy women
who were given a CLA supplement containing a mixture of 10
CLA isomers for 63 d (18). This isomeric blend is in contrast to
our supplement. CRP concentrations were significantly in-
creasedin obese men with signs of the metabolic syndrome (21).
The latter result may reflect the isomer-specific effect of t10,c12
CLA.CRP stimulates tissue factor production,which isthe main
stimulus for initiating coagulation (49). Therefore, reduced
plasma fibrinogen and CRP concentrations indicate that CLA
may attenuate thrombosis.
Baseline plasma concentrations of c9,t11 CLA and the per-
centage increase after CLA supplementation are comparable to
those in previous supplementation studies (17, 52, 53). In con-
trast, there were negligible concentrations of t10,c12 CLA in
baseline samples, and they did not increase after CLA supple-
mentation, despite the fact that the supplement providedt10,c12
CLA. The difficulty in detecting the t10,c12 CLA isomer has
been documented previously (17). Two hypotheses for this ob-
servation have been suggested. First, the t10,c12 CLA may be
Mean fasting plasma and lipoprotein cholesterol and triacylglycerol concentrations before and after conjugated linoleic acid (CLA) supplementation or
placebo for 8 wk
Control group
(n ҃ 16)
CLA group
(n ҃ 16)
Week 0 Week 8 Week 0 Week 8
Plasma Cholesterol (mmol/L) 4.73 0.26 4.78 0.23 5.16 0.17
5.06 0.14
Cholesterol (mmol/L)
LDL 3.10 0.22 3.18 0.20 3.63 0.18 3.31 0.19
Total HDL 1.50 0.10 1.54 0.08 1.44 0.07 1.55 0.08
0.23 0.03 0.25 0.03 0.23 0.04 0.34 0.05
1.26 0.08 1.29 0.07 1.21 0.05 1.21 0.05
0.20 0.03 0.21 0.03 0.19 0.03 0.28 0.05
LDL:HDL 2.15 0.17 2.13 0.16 2.63 0.21 2.26 0.21
Plasma triacylglycerol (mmol/L) 1.60 0.16 1.51 0.18 1.62 0.12 1.64 0.13
VLDL triacylglycerol (mmol/L) 0.66 0.08 0.56 0.07 0.76 0.09 0.78 0.7
VLDL cholesterol (mmol/L) 0.28 0.05 0.24 0.03 0.30 0.04 0.33 0.04
VLDL apolipoprotein B (
g/mL) 43.91 6.36 39.93 5.0 42.03 3.57 49.09 4.64
All values are x SEM. VLDL, very-low-density lipoprotein.
Significant difference within group after 8-wk supplementation (three-way ANOVA):
P 0.05,
P 0.01.
Significant difference between groups after 8 wk of supplementation, P 0.05 (analysis of covariance).
by guest on June 13, 2013ajcn.nutrition.orgDownloaded from
more easily oxidized because of its structure, and this would
allow it to bypass a number of rate-limiting steps in the peroxi-
-oxidation pathway (54). Alternatively, Sebedio et al
(55) showed that the t10,c12 CLA isomer is metabolized into
20:4 5,8,12,14 and 20:3 8,12,14 via desaturation and elon-
gation pathways. Consequently, t10,c12 CLA is not efficiently
incorporated into plasma lipids.
In conclusion, CLA supplementation did not have a positive
effecton insulin andglucose concentrations in persons with type
2 diabetes. Whereas we did show positive effects of CLA on
HDL-cholesterol and fibrinogen concentrations, the relative im-
portance of one CVD risk factor over another is unknown. Com-
in total plasma lipid fraction, which was comparable with pre-
viously reported data (17, 52). Any truly effective dietary strat-
egywouldimproveCVD risk factorswithoutany negative effect
on other components of the metabolic syndrome.
We are indebted to the study participants for their enthusiasm and com-
FMprepared themanuscriptand conductedmostoftheexperiments. TPY
conducted the clinicalinvestigations.AMassistedin the experimental work.
JJNwas involvedin theformulation ofthescientifichypothesisforthisstudy
and provided significant advice. HMR formulated the scientific hypothesis
and experimental design and prepared the manuscript. None of the authors
have any commercial interest in CLA, and noneof the authors hadany other
conflict of interest.
1. Hu FB, Van Dam RM, Liu S. Diet and risk of type II diabetes: the role
of types of fat and carbohydrate. Diabetologia 2001;44:80517.
2. SteppanCM,BaileyST,BhatS,etal.The hormoneresistin linksobesity
to diabetes Nature 2001;409:30712.
3. Alberti KGMM,Zimmet PZ. Definition, diagnosis and classification of
diabetes mellitus andits complications: part 1: diagnosis and classifica-
tion of diabetes mellitus: provisional report of a WHO consultation.
Diabet Med 1998;15:53953.
4. Das UN.Is metabolic syndromeX an inflammatorycondition?Exp Biol
Med (Maywood) 2002;227:98997.
5. Leinonen E, Hurt-Camejo E, Wiklund O,Hultén LM, Hiukka A, Taski-
nen MR. Insulin resistance and adiposity correlate with acute-phase
reaction and soluble celladhesion molecules in type 2diabetes.Athero-
sclerosis 2003;166:38794.
6. Erkelens DW.Insulinresistance syndrome andtypeII diabetes mellitus.
Am J Cardiol 2001;88(suppl):J3842.
7. Roche HM, Noone E, Sewter C, et al. Isomer dependent metabolic
ers: SREBP-1c and LXR
. Diabetes 2002;51:203744.
8. Gavino VC, GavinoG,LeblancMJ, Tuchweber B. An isomericmixture
ofconjugatedlinoleic acids butnot pure cis-9,trans-11-octadecadienoic
acid affects body weight gain and plasma lipids in hamsters. J Nutr
9. ParkY, AlbrightKL,Liu W,StorksonJM,CookME,ParizaMW.Effect
of conjugated linoleic acid on body composition in mice. Lipids 1997;
10. West DB, DeLany JP, Camet PM, Bolhm F, Truett AA, Scimeca JA.
Effectsofconjugated linoleicacid onbodyfat andenergymetabolismin
the mouse. Am J Physiol 1998;275(suppl):R66772.
11. DeLany JP, Bolhm F, Truett AA, Scimeca JA, West DB. Conjugated
linoleic acid reduces body fat content in mice without affecting energy
intake. Am J Physiol 1999;276(suppl):R11729.
12. Wilson TA, Nicolosi RJ, Chrysam M, Kritchevsky D. Conjugated lino-
leic acid reduces early aortic atherosclerosis greater than linoleic acidin
hypercholesterolemic hamsters. Nutr Res 2000;20:1795805.
13. Kritchevsky D,Tepper SA, WrightS, Tso P,CzarneckiSK. Influenceof
conjugated linoleic acid (CLA) on establishment and progression of
atherosclerosis in rabbits. J Am Coll Nutr 2000;19(suppl):S4727.
14. Toomey S, Roche H, Fitzgerald D, Belton O. Regression of pre-
established atherosclerosis in the apoE-/- mouse by conjugated linoleic
acid. Biochem Soc Trans 2003;31:10759.
15. Larsen TM, Toubro S, Astrup A. Efficacy and safety of dietary supple-
ments containing conjugated linoleic acid (CLA) for the treatment of
obesityevidence from animal and human studies. J Lipid Res 2003;
16. Blankson H, Stakkestad JA, Fagertun H, Thom E, Wadstein J, Gud-
mundsenO.Conjugatedlinoleicacidreducesbodyfat inoverweightand
obese subjects. J Nutr 2000;130:29438.
17. Noone E, Roche HM, Nugent AP, Gibney MJ. The effect of dietary
supplementation using isomeric blends of conjugated linoleic acid on
lipid metabolism in healthyhuman subjects. Br J Nutr2002;88:24351.
18. BenitoP,NelsonGJ, KelleyDS,BartoliniG,SchmidtPC,Simon V.The
effect of conjugated linoleic acid on platelet function, platelet fatty acid
composition, and blood coagulation in humans. Lipids 2001;36:2217.
19. Mougois V, Matsakas A, Petridou A, et al. Effect of supplementation
withconjugatedlinoleic acidonhuman serumlipids and bodyfat. J Nutr
Biochem 2001;12:58594.
20. Risérus U, Brismar K, Arner P, Veesby B. Treatment with dietary
trans10cis12 conjugated linoleic acid causes isomer-specific insulin re-
sistance in obese men with the metabolic syndrome. Diabetes Care
21. Risérus U, Samar B, Jovinge S, Fredrikson GN, rnlöv J, Veesby B.
oxidative stress and elevated c-reactive protein: a potential link to fatty
acid-induced insulin resistance. Circulation 2002;106:19259.
22. Noone E, McBennett S, Gibney MJ, Roche HM. The isomer-specific
effects of conjugated linoleic acid on gene expression and lipid metab-
olism in male Ob/Ob mice. Proc Nutr Soc 2001;60:149A.
23. American Diabetes Association. Evidence-based nutrition principles
and recommendation for the treatment and prevention of diabetes and
related complications. Diabetes Care 2002;25:20212.
24. Gregory J, Foster K, Tyler H, Wiseman M. The dietary and nutritional
25. Wallace AJ, McCarthy SN, GibneyMJ.Intakesof saturated, monosatu-
ratedandpolyunsaturatedfat in Irish adults: findingsofthe North/South
Ireland food consumption survey. Proc Nutr Soc 2002;61:85A.
26. Korhonen M, Kastarinen M, Uusitupa M, Puska P, Nissinen A. The
effect of intensified diet counseling on the diet of hypertensive subjects
in primary health care: a 2-year open randomized controlled trial of
lifestyle intervention against hypertensionin eastern Finland. Prev Med
27. Harrington K, Robson PJ, Kiely M, Livingston MBE, Lambe J, Gibney
MJ. The North/South Ireland food consumption survey: survey design
and methodology. Public Health Nutr 2001;4:103742.
28. JacksonK,RobertsonMD,FieldingBA,FraynKN,WilliamsCM.Olive
oil increases the number of triacylglycerol-rich chylomicron particles
compared with other oils: an effect retained when a second meal is fed.
Am J Clin Nutr 2002;76:9429.
29. Brustolin D, Maierna M, Aguzzi F, Zoppi F, Tarenghi G, Berti G.
Immunoturbidimetric method for routinedeterminationsof apolipopro-
teins A1 and B. Clin Chem 1991;37:7427.
30. Norris LA, Joyce M, OKeeffe N, Sheppard BL, Bonnar J. Haemostatic
risk factors inhealthy postmenopausal women taking hormone replace-
ment therapy. Maturitas 2002;25:12533.
31. Folch J, Lees M, Stanley GHS. A simple method for the isolation and
purification of total lipids from animal tissue. J Biol Chem 1957;226:
32. Taylor RW, Keil D, Gold EJ, Williams SM, Goulding A. Body mass
index, waist girth, andwaist-to-hipratio as indexes of totaland regional
adiposity in women: evaluation in women: evaluation using receiver
operating characteristic curves. Am J Clin Nutr 1998;67:449.
33. MatthewsJNS,AltmanDG,CampbellMJ,RoystonP.Analysis ofserial
measurements in medical research. Br Med J 1990;300:2305.
34. Allison DB, Paultre F, MaggioC, MezzitisN,Pi-Sunyer FX. The use of
area under curves in diabetes research. Diabetes Care 1995;18:24550.
35. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF,
functionfromfastingplasma glucose andinsulinconcentrationsin man.
Diabetologia 1985;28:4129.
36. KatzA,NambiSS,MatherK,etal.Quantitativeinsulinsensitivitycheck
index: a simple, accurate method for assessing insulin sensitivity in
humans. J Clin Endocrinol Metab 2000;85:240210.
by guest on June 13, 2013ajcn.nutrition.orgDownloaded from
37. MatsudaM,DeFronzoRA.Insulinsensitivityindicesobtainedfromoral
glucose tolerance testing: comparison with the euglycemic insulin
clamp. Diabetes Care 1999;22:146270.
38. MariA,PaciniG,MurphyE,LudvikB,NolanJJ.Amodel-basedmethod
for assessing insulin sensitivity from the oral glucose tolerance test.
Diabetes Care 2001;24:53948.
39. Bonora E, Muggeo M. Postprandial blood glucose as a risk factor for
cardiovasculardisease intypeII diabetes:the epidemiologicalevidence.
Diabetologia 2001;4:210714.
40. Tsuboyama-Kasaoka N, Takahashi M, Tanemura K, et al. Conjugated
linoleic acid supplementation reduces adipose tissue by apotosis and
develops lipodystrophy in mice. Diabetes 2000;49:153442.
41. Houseknecht KL, Vanden Heuvel JP, Moya-Camarena, et al. Dietary
conjugated linoleic acid normalises impaired glucose tolerance in the
Zucker diabetic fatty fa/fa rat. Biochem Biophys Res Commun 1998;
42. RyderJW,PortocarreroCP,SongXM,etal.Isomer-specificantidiabetic
properties of conjugated linoleic acid:improved glucose tolerance, skel-
etal muscle insulin action and UCP-2 gene expression. Diabetes 2001;
43. NIH Consensus Statement. Triglyceride, high-density lipoprotein, and
coronary heart disease. JAMA 1993;269:50510.
44. Tall AR, Jiang X, Luo Y, Silver D. 1999 George Lyman Duff memorial
lecture: lipid transfer proteins, HDL metabolism, and atherogenesis.
Arterioscler Thromb Vasc Biol 2000;20:11858.
45. Autran D, Attia N, Debecjus M, Durlach V, Girard-Globa A. Postpran-
dial reverse cholesterol transport in type 2 diabetic patients: effect of
lipid lowering treatment. Atherosclerosis 2000;153:45360.
46. Rader DJ, Davidson MH, Caplan RJ, Pears JS. Lipid and lipoprotein
ratios: association with coronary artery disease and effects of rosuvas-
tatin compared with atorvastatin, pravastatin, and simvastatin. Am J
Cardiol 2003;91(A):20C3C.
47. Smedman A, Veesby B. Conjugated linoleic acid supplementation in
humans-metabolic effects. Lipids 2001;36:77381.
48. Christ ER, Carroll PV, Albany E, et al. Normal VLDL metabolism
despite altered lipoprotein composition in type I diabetes mellitus. Clin
Endocrinol 2001;55:77787.
49. Yudkin JS,StehouwerCDA, Emeis JJ,CoppackSW. C-reactive protein
in healthy subjects: associations with obesity, insulin resistance, and
endothelial dysfunction: a potential role for cytokines originating from
adipose tissue. Arterioscler Thromb Vasc Biol 1999;19:9728.
50. Frohlich J, Steiner G. Dyslipidaemia and coagulation defects of insulin
resistance. Int J Clin Pract 2000;113(suppl):1422.
51. Norris LA. Blood coagulation. Best Pract Res Clin Obstet Gynaecol
52. Jiang J, Wolk A, Veesby B. Relation between the intake of milk fat and
theoccurrence ofconjugated linoleicacid inhumanadiposetissue.AmJ
Clin Nutr 1999;70:217.
53. Britton M, Fong C, Wickens D, Yudkin J. Diet as a source of phospho-
lipid esterified 9,11-octadecadienoic acid in humans. Clin Sci 1992;83:
54. Martin JC, Gregoire S, Siess MH, et al. Effects of conjugated linoleic
acid isomers on lipid metabolising enzymes in male rats. Lipids 2000;
55. Sebedio JL, Juaneda P, Dobson G, et al. Metabolites of conjugated
isomers of linoleic acid (CLA) in the rat. Biochim Biophys Acta 1997;
by guest on June 13, 2013ajcn.nutrition.orgDownloaded from
... Increased fasting glucose concentrations and reduced insulin sensitivity. Moloney et al. (2004) Healthy overweight and obese male and female adults (118). A randomized, double-blind, placebocontrolled trial. ...
... Linoleic acid reduced atherogenic lipoprotein level but did not affect glycemic control and carbohydrate tolerance. A study was conducted on patients with type 2 diabetes mellitus to investigate the effect conjugated linoleic acid supplementation on markers of glucose and insulin metabolism, lipoprotein metabolism, and inflammatory markers (Moloney et al., 2004). The administration of linoleic acid supplementation at dose of 3.0 g/d for 8 weeks increased fasting glucose concentrations and reduced insulin sensitivity as measured by homeostasis model assessment. ...
Background Moroccan flora is rich with medicinal plants that are widely used in traditional medicine for the treatment of various diseases including diabetes. These plants possess several classes of bioactive molecules, which belong to different chemical families such as phenolic acids, flavonoids, terpenoids and alkaloids. Scope and approach This review highlights the published reports on the antidiabetic properties of Moroccan medicinal plants. The mechanism of action of these plants and their secondary metabolites were discussed in detail. Clinical trials on the antidiabetic active constituents were summarized demonstrating the potential application of these natural treasures to be developed as potent antidiabetic agents. Key findings and conclusions were reported to be used in the treatment of diabetes in Morocco. Among these medicinal plants, the antidiabetic activity was evaluated for 15 species in vitro and 30 species in vivo. The in vitro studies showed significant inhibition of enzymes involved in the intestinal metabolism of carbohydrates. The in vivo reports revealed that the extracts and essential oils of these plants exhibited several antidiabetic effects such as a decrease of blood glucose and an increase of insulin secretion. Phytochemical analysis of the active plants revealed the presence of 148 secondary metabolites. These compounds belong to different chemical classes such as terpenoids, flavonoids, alkaloids, phenolic acids, and fatty acids. Among the identified compounds, 95 were evaluated for their antidiabetic activity. The results showed that these compounds manage diabetes by several mechanisms such as enzymatic inhibition, interference with glucose and lipid metabolism signaling pathways, and the inhibition and/or the activation of gene expression involved in glucose homeostasis. Eighteen active compounds reached clinical trials and showed impressive results in controlling diabetes and its manifestations.
... The content of c9,t11-CLA in suckling lamb meat is in line with those reported in other studies on suckling [26] and weaned lambs [38]. Clinical and animal studies have suggested anti-inflammatory and immunomodulatory antiatherogenic activities of c9,t11-CLA [57][58][59], as well as lowering cholesterol [60][61][62] and hyperinsulinemia prevention [63,64] effects. The anticarcinogenic effect of c9,t11-CLA has been widely observed in several studies on cell cancer lines and laboratory animals [58], but these results need to be confirmed in humans. ...
Full-text available
The effects of the dams and suckling lamb feeding systems on the fatty acid (FA) profile of lamb meat are reviewed in this article. The suckling lamb can be considered a functional monogastric, and therefore, its meat FA composition is strongly influenced by the FA composition of maternal milk. The major source of variation for ewe milk FA composition is represented by pasture amount and type. In the traditional sheep breeding system of the Mediterranean area, the main lambing period occurs in late autumn–early winter, and ewes are able to exploit the seasonal availability of the natural pastures at their best. Therefore, lambs start suckling when maternal milk concentrations of vaccenic, rumenic, and n-3 long-chain polyunsaturated FA in maternal milk are the highest. When maternal diet is mainly based on hay and concentrates, the use of vegetable oils can be considered a good strategy to improve the meat FA profile of suckling lambs.
... In addition, DHA is known to be of utmost importance for the proper development and functioning of the nervous system [9]. Conjugated linoleic acids (CLA) and conjugated linolenic acids (CLnA) have been shown to have a wide range of biological activities, among which antidiabetic [10,11], anti-inflammatory [12] and anti-cancer properties [13,14]. The bulk of CLA is supplied to humans by the diet, especially through the consumption of dairy products and ruminant meat [15], but dietary intake remains relatively low as CLA account for less than 2% of total ruminant fat. ...
Full-text available
Long-term feeding trials examining the incorporation of conjugated linolenic acids (CLnA) into the diet of laying hens are lacking. In the present study, we compared two diets in sixty-six red Sex-Link hens (33 hens/treatment), fed for 26 weeks. The control diet was high in oleic acid, while the test diet was high in α-linolenic acid (ALA) and punicic acid (PunA). No significant differences were observed between treatments for hens’ performance, egg weight and yolk weight. In contrast, dietary ALA and PunA resulted in a significant increase in n-3 PUFA, rumenic acid (RmA) and PunA contents in egg yolk, as well as in the liver, heart, muscle and adipose tissue of the hens. Other conjugated dienes resulting from the metabolism of PunA or RmA also accumulated in the egg yolk and tissues. Unlike DHA, which was exclusively distributed in phospholipids, ALA, RmA and PunA were preferably distributed in triglycerides.
... The t10c12 isomer may be the form responsible for the effects on weight loss and body fat deposition in animals (Park, Storkson et al. 1999) (Ryder, Portocarrero et al. 2001). However, in human studies, results on CLA are controversial, with studies showing effects on fat mass, serum total lipids, decrease whole body glucose uptake (Blankson, Stakkestad et al. 2000) (Raff, Tholstrup et al. 2009) and other studies contradicting the beneficial effects (Dhurandhar, Blank et al. 1999) (Zambell, Keim et al. 2000), (Moloney, Yeow et al. 2004). The dosage, the length of the treatment and the degree of obesity are factors that can affect the consistency of clinical results ). ...
White adipose tissue (WAT) plays a central role in the physiopathology of obesity and insulin resistance. During my PhD, I studied the cellular and molecular response of WAT to metabolic stress induced in mice by the administration of an isomer of linoleic acid (CLA). We used trans10,cis12 isomer of linoleic acid (t10,c12-CLA) as a tool to promote a lipoatrophic syndrome in C57BL/6J lean female mice. The short-term dynamics of this response was explored in WAT, gut and at systemic level, over two consecutive 7-day periods of t10,c12-CLA administration and withdrawal. Our results show that t10,C12-CLA-induced alterations in WAT included metabolic gene deregulation and extracellular matrix deposition. The immunological profile of WAT was markedly disturbed, with anti-inflammatory M2-polarized macrophage accumulation. Metabolic, immune and structural alteration were fully revered, but not always normalized after 7 days without treatment. The reversibility of WAT alterations indicates a more adaptive than pathological response to t10,C12-CLA. However, t10,c12-CLA-induced WAT deregulation is temporally linked to hyperinsulinemia supporting the primacy of WAT integrity for glucose homeostasis. No immune alteration was observed in response to t10,C12-CLA in the gut, where genes encoding tight junction proteins (claudin and occludin) were down regulated. Thus, part of the effects of t10,c12-CLA could be mediated by increased intestinal permeability. This study shows that in response to an acute nutritional stressor, WAT and glucose homeostasis could be rapidly regained. When the stress is more chronic, as in obesity, most of the interventions fail to reverse WAT dysfunctional state, underlining the big challenge in the years ahead of finding long-term therapeutic strategies in metabolic diseases.
This systematic review and meta-analysis assessed the antidiabetic effect of pharmaconutrients as an add-on in type 2 diabetes mellitus patients by pooling data from currently available randomized controlled trials (RCTs). Data sources included the PubMed and EMBASE, Cochrane Central Register of Controlled Trials. RCTs reporting changes in glycosylated hemoglobin (HbA1c), fasting blood glucose (FBG), or homeostasis model assessment of insulin resistance (HOMA-IR) levels following add-on pharmaconutritional therapies for T2DM patients consuming antidiabetic drugs were targeted. Using random-effects meta-analyses, we identified pharmaconutrients with effects on glycemic outcomes. Heterogeneity among studies was presented using I2 values. Among 9537 articles, 119 RCTs with nine pharmaconutrients (chromium; coenzyme Q10; omega-3 fatty acids; vitamins C, D, and E; alpha-lipoic acid; selenium; and zinc) were included. Chromium (HbA1c, FBG, and HOMA-IR), coenzyme Q10 (HbA1c and FBG), vitamin C (HbA1c and FBG), and vitamin E (HbA1c and HOMA-IR) significantly improved glycemic control. Baseline HbA1c level and study duration influenced the effects of chromium and vitamin E on HbA1c level. Sensitivity analyses did not modify the pooled effects of pharmaconutrients on glycemic control. Administration of chromium, coenzyme Q10, and vitamins C and E for T2DM significantly improved glycemic control. This study has been registered in PROSPERO (CRD42018115229).
Background and aims: The current study aimed to review the effects of dairy foods on lipid profile in randomized controlled clinical trials (RCTs). Methods: We searched PubMed, Scopus, Embase, and Central. RCTs that assess the effects of dairy foods on lipid profile were included. Results: The overall effects of dairy foods on lipid profile were non-significant. Dairy foods were associated with a non-significant reduction in triacylglycerol level, and a non-significant increase in total cholesterol, low density lipoprotein cholesterol, and high-density lipoprotein cholesterol level. Conclusion: We conclude that dairy foods doesn't have any unfavorable effects on lipids.
BACKGROUND: Inflammation is considered as one of the major factors in chemoradiotherapy toxicity. It has been reported that conjugated linoleic acid (CLA) has anti-inflammatory properties. OBJECTIVE: The aim of this study was to assess the effect of CLA supplementation on serum levels of leptin, interleukin 8 (IL-8), malondialdehyde (MDA), total antioxidant status (TAS), and carcinoembryonic antigen (CEA) in rectal cancer patients treated with chemoradiotherapy. METHODS: In this study, 34 rectal cancer patients were allocated to either the CLA group, who received four 1000 mg capsules (each capsule containing 760 mg CLA; 4 capsules providing 3 g CLA) 3 times/day, or the placebo group, who received 4 placebo capsules 3 times/day, for 6 weeks. RESULTS: The mean serum leptin level insignificantly increased in both groups; however, this elevation was remarkable in the CLA group. CLA supplementation reduced IL-8 by –0.62 pg/mL while placebo supplementation decreased it by –0.44 pg/mL. CEA levels were decreased by CLA supplementation, while its reduction in the placebo group was negligible compared to the CLA group. The elevation of MDA levels after CLA supplementation was about half of the placebo group in the CLA group. CONCLUSION: Since this study was the first to assess the effect of CLA supplementation on a small number of cancer patients, it is suggested further studies are conducted on larger sample size with various doses of CLA to obtain more clear results.
Obesity is a pandemic disease with immense magnitude and it is due to escalating death with co-morbidity in this century. Obesity is caused by combinatorial factors including genetic, metabolic, behavioral, environmental, cultural, and socioeconomic factors that contribute to a person’s body weight. This condition parse is alarmingly big magnitude problem and it is conformingly with the co-morbidities. An elevated body mass index (BMI) increases the prevalence, morbidity, and mortality of type 2 diabetes mellitus, hypertension, heart disease, stroke, osteoarthritis, respiratory tract disorders, gallstones, certain types of cancer, and psychological disorders. It is striking that only a few therapeutic agents are available to treat obesity including orlistat, sibutramine, lorcaserin, phentermine-topiramate available to treat obesity. These agents can reduce body weight by decreasing the consumption or absorption of food or by augmenting energy disbursement. In recent decades, the limelight of nanotechnology has opened numerous new vistas in medical sciences, especially in the area of drug delivery. The nanoparticulate drug delivery system can transport specific anti-obesity drugs to the white adipose tissue in the body, aiding to evade potential side effects that can occur if the drugs find their way to other parts of the body. In this chapter, we highlighted the various nano-drug delivery systems including polymeric nanoparticles, chitosan nanoparticles, Polyethylene glycol-based nanoparticles, gold nanoparticles, liposomes, transfersomes, and microparticles to enhance the therapeutic efficacy against obesity treatment.
It is now recognized that the amount and type of dietary fat consumed play an important role in metabolic health. In humans, high intake of polyunsaturated fatty acids (PUFAs) has been associated with reductions in cardiovascular disease risk, improvements in glucose homeostasis, and changes in body composition that involve reductions in central adiposity and, more recently, increases in lean body mass. There is also emerging evidence, which suggests that high intakes of the plant‐based essential fatty acids (ePUFAs)—n‐6 linoleic acid (LA) and n‐3 α‐linolenic acid (ALA)—have a greater impact on body composition (fat mass and lean mass) and on glucose homeostasis than the marine‐derived long‐chain n‐3 PUFA—eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). In addition, high intake of both ePUFAs (LA and ALA) may also have anti‐inflammatory effects in humans. The purpose of this review is to highlight the emerging evidence, from both epidemiological prospective studies and clinical intervention trials, of a role for PUFA, in particular ePUFA, in the long‐term regulation of body weight and body composition, and their impact on cardiometabolic health. It also discusses current notions about the mechanisms by which PUFAs modulate fat mass and lean mass through altered control of energy intake, thermogenesis, or lean–fat partitioning.
Full-text available
Conjugated linoleic acid (CLA) is a heterogeneous group of positional and geometric isomers of linoleic acid. This study demonstrates the divergent effects of the cis-9 trans-11 (c9,t11-CLA) and trans-10 cis-12 (t10,c12-CLA) isomers of CLA on lipid metabolism and nutrient regulation of gene expression in ob/ob mice. The c9, t11-CLA diet decreased serum triacylglycerol (P = 0.01) and nonesterified fatty acid (NEFA) (P = 0.05) concentrations, and this was associated with reduced hepatic sterol regulatory element-binding protein-1c (SREBP-1c; P = 0.0045) mRNA expression, coupled with reduced levels of both the membrane-bound precursor and the nuclear forms of the SREBP-1 protein. C9,t11-CLA significantly reduced hepatic LXRalpha (P = 0.019) mRNA expression, a novel regulator of SREBP-1c. In contrast, c9,t11-CLA increased adipose tissue SREBP-1c mRNA expression (P = 0.0162) proportionally to the degree of reduction of tumor necrosis factor alpha (TNF-alpha) mRNA (P = 0.012). Recombinant TNF-alpha almost completely abolished adipose tissue SREBP-1c mRNA expression in vivo. The t10,c12-CLA diet promoted insulin resistance and increased serum glucose (P = 0.025) and insulin (P = 0.01) concentrations. T10, c12-CLA induced profound weight loss (P = 0.0001) and increased brown and white adipose tissue UCP-2 (P = 0.001) and skeletal muscle UCP-3 (P = 0.008) mRNA expression. This study highlights the contrasting molecular and metabolic effect of two isomers of the same fatty acids. The ameliorative effect of c9,t11-CLA on lipid metabolism may be ascribed to reduced synthesis and cleavage of hepatic SREBP-1, which in turn may be regulated by hepatic LXRalpha expression.
Full-text available
We report the effect of an atherogenic diet supplemented with cis-9, trans-11-octadecadienoic acid (c9t11), linoleic acid (LA) or an isomeric mixture of conjugated linoleic acids (CLA) on plasma lipids, weight gain and food intake of male Golden Syrian hamsters. Animals were assigned to three diet groups (n = 10), and fed nonpurified diet, supplemented with 10% hydrogenated coconut oil and 0.05% cholesterol for 6 wk. The first diet group was further supplemented with 1% CLA (CLA group), the second diet group with 0.2% c9t11 (c9t11 group) and the third group with 0.2% LA (LA group). The diets were designed to have equivalent levels of c9t11 in the CLA and c9t11 groups. At 2 and 6 wk of feeding, the CLA group had significantly lower plasma triglyceride and total cholesterol concentrations than either the c9t11 or the LA groups. HDL-cholesterol did not differ among diet groups. The CLA group had significantly lower weight gain but greater food intake than either the c9t11 or the LA groups. There were no significant differences between the c9t11 and the LA groups in any of the variables measured. We conclude that under our experimental conditions of short-term feeding, c9t11, thought to be the active compound in CLA, does not produce the same effect as the isomer mixture.
We report the effect of an atherogenic diet supplemented with cis-9,trans-11-octadecadienoic acid (c9t11), linoleic acid (LA) or an isomeric mixture of conjugated linoleic acids (CLA) on plasma lipids, weight gain and food intake of male Golden Syrian hamsters. Animals were assigned to three diet groups (n = 10), and fed nonpurified diet, supplemented with 10% hydrogenated coconut oil and 0.05% cholesterol for 6 wk. The first diet group was further supplemented with 1% CLA (CLA group), the second diet group with 0.2% c9t11 (c9t11 group) and the third group with 0.2% LA (LA group). The diets were designed to have equivalent levels of c9t11 in the CLA and c9t11 groups. At 2 and 6 wk of feeding, the CLA group had significantly lower plasma triglyceride and total cholesterol concentrations than either the c9t11 or the LA groups. HDL-cholesterol did not differ among diet groups. The CLA group had significantly lower weight gain but greater food intake than either the c9t11 or the LA groups. There were no significant differences between the c9t11 and the LA groups in any of the variables measured. We conclude that under our experimental conditions of short-term feeding, c9t11, thought to be the active compound in CLA, does not produce the same effect as the isomer mixture.
Conjugated linoleic acid (CLA) is a naturally occurring group of dienoic derivatives of linoleic acid found in the fat of beef and other ruminants. CLA is reported to have effects on both tumor development and body fat in animal models. To further characterize the metabolic effects of CLA, male AKR/J mice were fed a high-fat (45 kcal%) or low-fat (15 kcal%) diet with or without CLA (2.46 mg/kcal; 1.2 and 1.0% by weight in high- and low-fat diets, respectively) for 6 wk. CLA. significantly reduced energy intake, growth rate, adipose depot weight, and carcass lipid and protein content independent of diet composition. Overall, the reduction of adipose depot weight ranged from 43 to 88%, with the retroperitoneal depot most sensitive to CLA. CLA significantly increased metabolic rate and decreased the nighttime respiratory quotient. These findings demonstrate that CLA reduces body fat by several mechanisms, including a reduced energy intake, increased metabolic rate, and a shift in the nocturnal fuel mix.
Thirty-six male F1B hamsters, 10 weeks of age, were divided into 3 groups of 12 based on similar body weights. The experimental diets comprised of a chow-based hypercholesterolemic diet supplemented with 20% coconut oil, 2% safflower oil, and 0.12% cholesterol (HCD); the HCD plus either 1% CLA as the free fatty acid (CLA), or 1% LA as the free fatty acid (LA) and were fed for 12 weeks. Plasma total cholesterol (TC) and nonHDL-C (very low- and low-density lipoprotein cholesterol) were significantly lower in the CLA and LA relative to the HCD (P < 0.05). The CLA had significantly less maximum number of dienes formed relative to the LA and HCD (P < 0.05). The CLA developed significantly less early aortic atherosclerosis relative to both the HCD and LA (P < 0.05). Thus it appears CLA reduces the development of early aortic atherosclerosis to a greater degree than LA possibly through changes in LDL oxidative susceptibility in hypercholesterolemic hamsters.
GREAT progress has been made over the past 30 years in identifying cardiovascular risk factors and in developing and implementing measures to correct them. The Adult Treatment Panel of the National Cholesterol Education Program developed guidelines in 1988 that identified low-density lipoprotein (LDL) as the major atherogenic lipoprotein and high levels of LDL cholesterol (LDL-C) as the primary target for cholesterol-lowering therapy. Since these guidelines were developed, the scientific database has significantly expanded. Genetic investigations into familial dyslipidemias, advances in molecular biology, animal experiments, human observational studies, lipid metabolic studies, epidemiologic data, and the results of interventional clinical trials looking at mortality, cardiovascular end points, and angiographic changes in atheromatous lesions have created interest in further examination of the role of high-density lipoprotein cholesterol (HDL-C) and triglycerides (TGs) in the pathogenesis of coronary artery disease. To address these questions, the National Heart, Lung, and Blood Institute and the Office of
Conjugated linoleic acid (CLA) is a naturally occurring fatty acid which has anti-carcinogenic and anti-atherogenic properties. CLA activates PPAR alpha in liver, and shares functional similarities to ligands of PPAR gamma, the thiazolidinediones, which are potent insulin sensitizers. We provide the first evidence that CLA is able to normalize impaired glucose tolerance and improve hyperinsulinemia in the pre-diabetic ZDF rat. Additionally, dietary CLA increased steady state levels of aP2 mRNA in adipose tissue of fatty ZDF rats compared to controls, consistent with activation of PPAR gamma. The insulin sensitizing effects of CLA are due, at least in part, to activation of PPAR gamma since increasing levels of CLA induced a dose-dependent transactivation of PPAR gamma in CV-1 cells cotransfected with PPAR gamma and PPRE X 3-luciferase reporter construct. CLA effects on glucose tolerance and glucose homeostasis indicate that dietary CLA may prove to be an important therapy for the prevention and treatment of NIDDM.
1. Diene-conjugated fatty acids are one of the products of free-radical attack upon lipids and therefore have been used as markers of such attack. The major diene-conjugated fatty acid in human tissue and serum is an isomer of linoleic acid (9,12-octadecadienoic acid), namely 9,11-octadecadienoic acid. Diet may be another source of this isomer, raising questions as to its value as a free-radical marker. The aim of this study was to determine the importance of diet as a source of 9,11-octadecadienoic acid in phospholipid esterified fatty acids in human serum. 2. Foodstuffs rich in 9,11-octadecadienoic acid were identified. Fourteen subjects volunteered to alter their diets, either increasing ('high diet') or decreasing ('low diet') their intake of these foodstuffs for 3 weeks. Where subjects undertook both diets, a washout period of at least 3 weeks was allowed between phases. 3. Seven-day diet histories were kept and scored with respect to their content of 9,11-octadecadienoic acid. The concentrations of 9,11-octadecadienoic acid and linoleic acid in serum phospholipids were measured by h.p.l.c. with u.v. detection. 4. The percentage molar ratio of 9,11-octadecadienoic acid to linoleic acid was calculated. The percentage molar ratio rose significantly on the ‘high diet’ [1.3(0.4) versus 1.9(0.7), P=0.01, mean (SD)] and fell significantly on the ‘low diet’ [1.6(0.4) versus 1.1(0.4), P=0.004, means (SD)]. There was a significant correlation between the change in dietary intake of 9,11-octadecadienoic acid and the change in the percentage molar ratio (r= 0.829, P = 0.001). 5. The concentration of 9,11-octadecadienoic acid in serum phospholipids is influenced by diet. Its use as a marker of free-radical activity is questionable and at least in need of careful interpretation.